Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Locally Advanced Breast Cancer · Triple Negative Breast Cancer · Metastatic Triple Negative Breast Cancers
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 83 (final count)
- Started
- Aug 26, 2024
- Main results expected
- Aug 2028
- Fully finished
- Jun 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Occurrence of treatment emergent adverse events (TEAEs), adverse events of special interest (AESIs), treatment emergent serious adverse events (SAEs)
Measured over: up to 100 days after the last dose of treatment
Occurrence of dose interruption, dose reduction, and discontinuation of study treatment due to adverse events (AEs)
Measured over: up to 100 days after the last dose of treatment
Objective Response Rate (ORR)
Measured over: Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment
Best percentage change from baseline in the tumor size
Measured over: Until end-of-treatment visit, i.e., up to 24 months after the first dose of treatment
Proportion of participants who have achieved early tumor shrinkage
Measured over: up to 4 months after first dose of treatment
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06449222 · record last updated 2026-06-30 · checked 2026-11-09 15:47 UTC